{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-055468","form_type":"8-K","ticker":"SSII","cik":"0001676163","company_name":"SS Innovations International, Inc.","filed_at":"2026-05-13T12:30:18+00:00","discovered_at":"2026-05-13T12:35:08.231562+00:00","generated_at":"2026-05-13T12:35:53.657018+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SS Innovations Q1 revenue $11.1M (+117% YoY); net loss narrows to $3.6M; installations up 73%","bullets":["Revenue $11.1M, up 116.8% YoY from $5.1M; gross margin 48.0% vs 21.2% in Q1 2025.","Net loss $3.6M ($0.02/share) vs $5.7M ($0.03) in Q1 2025; cash $16.0M, no long-term debt.","SSi Mantra installations 26 (+73% YoY); cumulative installed base 194 across 11 countries; 9,744 cumulative surgeries.","Regulatory approvals: NMRA (Sri Lanka) and PPB (Kenya); telesurgery approvals in Indonesia and Philippines.","March 2026 private placement raised ~$18.6M gross; FDA 510(k) review expected in 2026 and CE marking pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055468","json":"https://secwatch.observer/filing/0001213900-26-055468.json","markdown":"https://secwatch.observer/filing/0001213900-26-055468.md","text":"https://secwatch.observer/filing/0001213900-26-055468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676163/000121390026055468/0001213900-26-055468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676163/000121390026055468/ea0290453-8k_ssinnovations.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:35:53.657018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ab67abe2a77b4d89c05facf74cb322b2921662b","claim":"SS Innovations International, Inc. reported the three months ended March 31, 2026 results: revenue $11.1 million, EPS $(0.02) per diluted share.","evidence_excerpt":"Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 Overview ● Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. ● Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. ● Gross profit rose 390.0% to $5.3 million from $1.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676163/000121390026055468/0001213900-26-055468-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$11.1 million"},{"label":"EPS","value":"$(0.02) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}